Mostrar el registro sencillo del ítem
dc.contributor.author | Hernandez-Agudo, Elena | |
dc.contributor.author | Mondejar, Tamara | |
dc.contributor.author | Soto-Montenegro, Maria Luisa | |
dc.contributor.author | Megias Vazquez, Diego | |
dc.contributor.author | Mouron, Silvana Andrea | |
dc.contributor.author | Sanchez, Jesus | |
dc.contributor.author | Hidalgo, Manuel | |
dc.contributor.author | Lopez-Casas, Pedro Pablo | |
dc.contributor.author | Mulero Francisca, Francisca | |
dc.contributor.author | Desco, Manuel | |
dc.contributor.author | Quintela Fandino, Miguel Angel | |
dc.date.accessioned | 2019-10-30T11:48:43Z | |
dc.date.available | 2019-10-30T11:48:43Z | |
dc.date.issued | 2016-05 | |
dc.identifier.citation | Mol Oncol. 2016;10(5):704-18. | es_ES |
dc.identifier.issn | 15747891 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/8537 | |
dc.description | This work was supported by the following sources: Fondo de Investigacion Sanitaria (Ministry of Health, Spain; numbers FIS PI10/0288, FIS PI13/00430, FIS PI 11/00616, CPII14/00005 and FIS PI14/00860; the first two awarded to MQF and the last three to MD), and "Fondo Europeo de Desarrollo Regional (FEDER) - Una manera de hacer Europa". MQF is a recipient of a 2010 Beca-Retorno from the AECC Scientific Foundation. Rosae Foundation and AVON Espana S.A.U. contributed to this work with unrestricted donations. Dovitinib was kindly provided by Novartis. | es_ES |
dc.description.abstract | BACKGROUND: Rationalization of antiangiogenics requires biomarkers. Vascular re-normalization is one widely accepted mechanism of action for this drug class. The interstitium of tumors with abnormal vasculature is hypoxic. We sought to track vascular normalization with (18)F-misonidazole ([18F]-FMISO, a probe that detects hypoxia) PET, in response to window-of-opportunity (WoO) treatment with the antiangiogenic dovitinib. METHODS: Two patient-derived pancreas xenografts (PDXs; Panc215 and Panc286) and the spontaneous breast cancer model MMTV-PyMT were used. Animals were treated during 1 week of WoO treatment with vehicle or dovitinib, preceded and followed by [18F]-FMISO-PET, [18F]-FDG-PET, and histologic assessment (dextran extravasation, hypoxia and microvessel staining, and necrosis, cleaved caspase-3 and Ki67 measurements). After WoO treatment, gemcitabine (pancreas)/adriamycin (breast) or vehicle was added and animals were treated until the humane endpoint. Tumor growth inhibition (TGI) and survival were the parameters studied. RESULTS: [18F]-FMISO SUV did not change after dovitinib-WoO treatment compared to vehicle-WoO (0.54 vs. 0.6) treatment in Panc215, but it decreased significantly in Panc286 (0.58 vs. 1.18; P < 0.05). In parallel, 10-KDa perivascular dextran extravasation was not reduced with dovitinib or vehicle-WoO treatment in Panc215, but it was reduced in Panc286. Whereas the addition of dovitinib to gemcitabine was indifferent in Panc215, it increased TGI in Panc286 (TGI switched from -59% to +49%). [18F]-FMISO SUV changes were accompanied by an almost 100% increase in interstitial gemcitabine delivery (665-1260 ng/mL). The results were validated in the PyMT model. CONCLUSIONS: [18F]-FMISO accurately monitored vascular re-normalization and improved interstitial chemotherapy delivery. | es_ES |
dc.description.sponsorship | This work was supported by the following sources: Fondo de Investigacion Sanitaria (Ministry of Health, Spain; numbers FIS PI10/0288, FIS PI13/00430, FIS PI 11/00616, CPII14/00005 and FIS PI14/00860; the first two awarded to MQF and the last three to MD), and "Fondo Europeo de Desarrollo Regional (FEDER) - Una manera de hacer Europa". MQF is a recipient of a 2010 Beca-Retorno from the AECC Scientific Foundation. Rosae Foundation and AVON Espana S.A.U. contributed to this work with unrestricted donations. Dovitinib was kindly provided by Novartis. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | (18)F-misonidazole-PET | es_ES |
dc.subject | Antiangiogenics | es_ES |
dc.subject | Biomarker | es_ES |
dc.subject | Breast cancer | es_ES |
dc.subject | Pancreatic cancer | es_ES |
dc.subject | Vascular normalization | es_ES |
dc.subject.mesh | Angiogenesis Inhibitors | es_ES |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Antimetabolites, Antineoplastic | es_ES |
dc.subject.mesh | Benzimidazoles | es_ES |
dc.subject.mesh | Breast | es_ES |
dc.subject.mesh | Breast Neoplasms | es_ES |
dc.subject.mesh | Cell Hypoxia | es_ES |
dc.subject.mesh | Cell Line, Tumor | es_ES |
dc.subject.mesh | Deoxycytidine | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Fluorine Radioisotopes | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Mice | es_ES |
dc.subject.mesh | Mice, Nude | es_ES |
dc.subject.mesh | Misonidazole | es_ES |
dc.subject.mesh | Neovascularization, Pathologic | es_ES |
dc.subject.mesh | Pancreas | es_ES |
dc.subject.mesh | Pancreatic Neoplasms | es_ES |
dc.subject.mesh | Positron-Emission Tomography | es_ES |
dc.subject.mesh | Quinolones | es_ES |
dc.title | Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 26778791 | es_ES |
dc.format.volume | 10 | es_ES |
dc.format.number | 5 | es_ES |
dc.format.page | 704-18 | es_ES |
dc.identifier.doi | 10.1016/j.molonc.2015.12.011 | es_ES |
dc.contributor.funder | Unión Europea | |
dc.contributor.funder | Asociación Española Contra el Cáncer | |
dc.contributor.funder | Ministerio de Sanidad y Consumo (España) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1878-0261 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.molonc.2015.12.011 | es_ES |
dc.identifier.journal | Molecular oncology | es_ES |
dc.repisalud.institucion | CNIO | es_ES |
dc.repisalud.orgCNIO | CNIO::Unidades técnicas::Unidad de Investigación Clínica de Cáncer de Mama | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/PI10/0288 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/PI13/00430 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/PI11/00616 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/CPII14/00005 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/PI14/00860 | es_ES |
dc.rights.accessRights | open access | es_ES |